News on research and diagnostics in autoimmune disorders including rheumatoid arthritis, lupus, multiple sclerosis, and more.
With genome sequences for nearly 900 individuals with primary immunodeficiency, researchers identified candidate genes and common variant contributors.
The company is now marketing what it calls its Pharma Research Solutions, including a more flexible array of molecular analyses than its existing NeXT platform.
Blueprint Genetics, recently acquired by Quest Diagnostics in January, will base the 600-gene panel on its whole-exome sequencing capability.
The alliance will initially focus on rheumatoid arthritis using biomarkers discovered using Nimble's human proteome immunoprofiling technology.
The immune sequencing firm has engaged the FDA in discussions over how to get regulatory approval for one test for several seemingly different diseases.
